Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation

Table 3 Body weight and blood sugar change at different time points (n > 3)

Time (week)	Body weight (g)				Blood glucose (mmol/L)
	Control	Model	BQKL	CaD	Control	Model	BQKL	CaD
0	267.00 ± 4.58	277.67 ± 11.68	273.00 ± 24.25	290.67 ± 14.98	7.50 ± 0.66	7.00 ± 0.70	7.77 ± 1.74	7.60 ± 1.08
4	457.00 ± 10.58	312.00 ± 6.08	346.33 ± 5.51	324.00 ± 25.71	7.17 ± 0.45	32.13 ± 0.21	31.60 ± 0.53	31.33 ± 0.15
8	493.67 ± 9.50	323.00 ± 17.35	376.33 ± 11.06	403.00 ± 4.68	8.20 ± 0.36	32.10 ± 0.26	30.90 ± 0.61	30.47 ± 0.38
12	556.00 ± 18.36	295.67 ± 12.01	413.00 ± 16.37	432.67 ± 14.19	8.50 ± 0.26	31.67 ± 0.55	29.50 ± 1.08	27.73 ± 0.76
16	597.00 ± 18.25	260.33 ± 14.84	443.67 ± 24.58	464.00 ± 10.15	7.00 ± 0.26	30.70 ± 0.90	28.23 ± 0.61	25.47 ± 0.74

BQKL: Buqing granule; CaD: Calcium dobesilate.